In vitro and in vivo activities of tigecycline-colistin combination therapies against carbapenem-resistant enterobacteriaceae

Jonathan W. Betts, Lynette M. Phee, Michael Hornsey, Neil Woodford, David W. Wareham*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

40 Citations (Scopus)

Abstract

We assessed the activity of tigecycline (TGC) combined with colistin (COL) against carbapenem-resistant enterobacteria. Synergy occurred in vitro against the majority of isolates, with the exception of Serratia marcescens. In a simple animal model (Galleria mellonella), TGC-COL was superior (P < 0.01) in treating Escherichia coli, Klebsiella pneumoniae, and Enterobacter infections, including those with TGC-COL resistance. Clinical studies are needed to determine whether TGC-COL regimens may be a viable option.

Original languageEnglish
Pages (from-to)3541-3546
Number of pages6
JournalAntimicrobial Agents and Chemotherapy
Volume58
Issue number6
DOIs
Publication statusPublished - Jun 2014

Fingerprint

Dive into the research topics of 'In vitro and in vivo activities of tigecycline-colistin combination therapies against carbapenem-resistant enterobacteriaceae'. Together they form a unique fingerprint.

Cite this